Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hangzhou Just Bio Raises $57 Million for Biologic Drug Development

publication date: Aug 8, 2017
Hangzhou Just Biotherapeutics (Just China), a company focused on providing affordable biologic drugs, completed a $57 million Series B funding. Just China is developing a portfolio of innovative and biosimilar products. Founded in early 2016 as a joint venture with Just Biotherapeutics (Just) of Seattle, Just China was established with the goal of shortening the development process and reducing the manufacturing cost of biologic drugs. The B round was led by Temasek of Singapore and joined by existing investors Lilly Asia Ventures and ARCH Venture Partners. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital